quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 9, 2025

Fed likely to cut rates at Dec. meeting, Paramount's hostile bid for WBD

View original at finance.yahoo.com
Fed likely to cut rates at Dec. meeting, Paramount's hostile bid for WBD Morning Brief host Julie Hyman tackles the biggest market stories ahead of the opening bell on December 9, 2025…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 25 basis point cut is important for investor sentiment, not necessarily for companies

    80% confidence
  • To prevent China outpacing US in AI, US needs to be participant in China market

    80% confidence
  • Market is definitely expecting a cut and is addicted to having this cut

    80% confidence
  • Intel and AMD would also be eligible for modified chip sales to China

    80% confidence
  • Short term Bitcoin holders have cost basis around $103,000 and tend to sell on rises

    80% confidence
  • Supreme Court majority seemed in favor of giving Trump more power to remove independent agency personnel

    80% confidence
  • Heavy debt load on Warner Bros from acquisition could challenge their ability to be successful

    80% confidence
  • Competition is critical for advanced technologies and giving China competitive access will propel market forward

    80% confidence
  • Risk level today has gone up quite a bit with people thinking deals can't fail

    80% confidence
  • CVS expects earnings to grow again in 2026

    80% confidence
  • Kevin Hassett is favorite to become new Fed chair in May

    80% confidence
  • Bitcoin could end the year below $100,000 despite earlier estimates of $150,000-$200,000

    80% confidence
  • Huawei is about 2 to 5 years behind Nvidia currently

    80% confidence
  • Fed will temper sentiment on rate cuts next year but investors need to watch labor market commentary

    80% confidence
  • Consumers remain intentional in their shopping behaviors but stand to benefit from at-home cooking trends

    80% confidence
  • CVS is closing out the year with meaningful momentum across its business

    80% confidence
  • Fed will cut 25 basis points but signal fewer cuts going forward in hawkish manner

    80% confidence
  • Trump informed Chinese President Xi Jinping about Nvidia chip approval and Xi responded favorably

    80% confidence
  • Investors need to sort of sit tight as we go into 2026

    80% confidence
  • Hawkish Fed cut would not be good for crypto in general

    80% confidence
  • Seeing exotic financial deals reminiscent of 1980s excess with private credit

    80% confidence
  • Referenced Tricolor bankruptcy as potential cockroach signal for credit markets

    80% confidence
  • Lot of money chasing few good deals leading to acceptance of previously unacceptable terms

    80% confidence
  • Allowing Nvidia into China will slow down domestic Chinese competition

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Fed likely to cut rates at Dec. meeting, Paramount's hostile bid for WBD — Source | Via News | pt.VIA.NEWS